179 related articles for article (PubMed ID: 34620512)
1. Pharmacological tools to target NKCC1 in brain disorders.
Savardi A; Borgogno M; De Vivo M; Cancedda L
Trends Pharmacol Sci; 2021 Dec; 42(12):1009-1034. PubMed ID: 34620512
[TBL] [Abstract][Full Text] [Related]
2. NKCC1 Chloride Importer Antagonists Attenuate Many Neurological and Psychiatric Disorders.
Ben-Ari Y
Trends Neurosci; 2017 Sep; 40(9):536-554. PubMed ID: 28818303
[TBL] [Abstract][Full Text] [Related]
3. CNS pharmacology of NKCC1 inhibitors.
Löscher W; Kaila K
Neuropharmacology; 2022 Mar; 205():108910. PubMed ID: 34883135
[TBL] [Abstract][Full Text] [Related]
4. Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B.
Hampel P; Römermann K; MacAulay N; Löscher W
Sci Rep; 2018 Jun; 8(1):9877. PubMed ID: 29959396
[TBL] [Abstract][Full Text] [Related]
5. Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy.
Brandt C; Seja P; Töllner K; Römermann K; Hampel P; Kalesse M; Kipper A; Feit PW; Lykke K; Toft-Bertelsen TL; Paavilainen P; Spoljaric I; Puskarjov M; MacAulay N; Kaila K; Löscher W
Neuropharmacology; 2018 Dec; 143():186-204. PubMed ID: 30248303
[TBL] [Abstract][Full Text] [Related]
6. Prevention of NKCC1 phosphorylation avoids downregulation of KCC2 in central sensory pathways and reduces neuropathic pain after peripheral nerve injury.
Mòdol L; Cobianchi S; Navarro X
Pain; 2014 Aug; 155(8):1577-1590. PubMed ID: 24813295
[TBL] [Abstract][Full Text] [Related]
7. A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy.
Gharaylou Z; Tafakhori A; Agah E; Aghamollaii V; Kebriaeezadeh A; Hadjighassem M
CNS Drugs; 2019 Mar; 33(3):283-291. PubMed ID: 30784026
[TBL] [Abstract][Full Text] [Related]
8. The loop diuretic torasemide but not azosemide potentiates the anti-seizure and disease-modifying effects of midazolam in a rat model of birth asphyxia.
Welzel B; Schmidt R; Kirchhoff L; Gramer M; Löscher W
Epilepsy Behav; 2023 Feb; 139():109057. PubMed ID: 36586153
[TBL] [Abstract][Full Text] [Related]
9. Bumetanide protects focal cerebral ischemia-reperfusion injury in rat.
Wang G; Huang H; He Y; Ruan L; Huang J
Int J Clin Exp Pathol; 2014; 7(4):1487-94. PubMed ID: 24817944
[TBL] [Abstract][Full Text] [Related]
10. Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice.
Hampel P; Römermann K; Gailus B; Johne M; Gericke B; Kaczmarek E; Löscher W
Neuropharmacology; 2021 Mar; 185():108449. PubMed ID: 33450274
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Na
Zhang J; Pu H; Zhang H; Wei Z; Jiang X; Xu M; Zhang L; Zhang W; Liu J; Meng H; Stetler RA; Sun D; Chen J; Gao Y; Chen L
Neurochem Int; 2017 Dec; 111():23-31. PubMed ID: 28577991
[TBL] [Abstract][Full Text] [Related]
12. Astrocytic NKCC1 inhibits seizures by buffering Cl
Nguyen TD; Ishibashi M; Sinha AS; Watanabe M; Kato D; Horiuchi H; Wake H; Fukuda A
Epilepsia; 2023 Dec; 64(12):3389-3403. PubMed ID: 37779224
[TBL] [Abstract][Full Text] [Related]
13. NKCC1 Inhibition Attenuates Chronic Cerebral Hypoperfusion-Induced White Matter Lesions by Enhancing Progenitor Cells of Oligodendrocyte Proliferation.
Yu Y; Fu P; Yu Z; Xie M; Wang W; Luo X
J Mol Neurosci; 2018 Mar; 64(3):449-458. PubMed ID: 29502291
[TBL] [Abstract][Full Text] [Related]
14. Beta-Amyloid (Aβ
Lam P; Vinnakota C; Guzmán BC; Newland J; Peppercorn K; Tate WP; Waldvogel HJ; Faull RLM; Kwakowsky A
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458638
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Nkcc1 promotes axonal growth and motor recovery in ischemic rats.
Mu XP; Wang HB; Cheng X; Yang L; Sun XY; Qu HL; Zhao SS; Zhou ZK; Liu TT; Xiao T; Song B; Jolkkonen J; Zhao CS
Neuroscience; 2017 Dec; 365():83-93. PubMed ID: 28964752
[TBL] [Abstract][Full Text] [Related]
16. Reply to the commentary by Ben-Ari and Delpire: Bumetanide and neonatal seizures: Fiction versus reality.
Löscher W; Kaila K
Epilepsia; 2021 Apr; 62(4):941-946. PubMed ID: 33764535
[TBL] [Abstract][Full Text] [Related]
17. The chloride co-transporters, NKCC1 and KCC2, in experimental autoimmune encephalomyelitis (EAE).
Yousuf MS; Zubkow K; Tenorio G; Kerr B
Neuroscience; 2017 Mar; 344():178-186. PubMed ID: 28057537
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous brain distribution of bumetanide following systemic administration in rats.
Löscher W; Gramer M; Römermann K
Biopharm Drug Dispos; 2024 Jun; 45(3):138-148. PubMed ID: 38823029
[TBL] [Abstract][Full Text] [Related]
19. The search for brain-permeant NKCC1 inhibitors for the treatment of seizures: Pharmacokinetic-pharmacodynamic modelling of NKCC1 inhibition by azosemide, torasemide, and bumetanide in mouse brain.
Hampel P; Römermann K; Gramer M; Löscher W
Epilepsy Behav; 2021 Jan; 114(Pt A):107616. PubMed ID: 33279441
[TBL] [Abstract][Full Text] [Related]
20. NKCC1 up-regulation contributes to early post-traumatic seizures and increased post-traumatic seizure susceptibility.
Wang F; Wang X; Shapiro LA; Cotrina ML; Liu W; Wang EW; Gu S; Wang W; He X; Nedergaard M; Huang JH
Brain Struct Funct; 2017 Apr; 222(3):1543-1556. PubMed ID: 27586142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
